具有抗癌作用的药物再定位：减少易感个体癌症发病率的贡献。
Drug Repositioning With an Anticancer Effect: Contributions to Reduced Cancer Incidence in Susceptible Individuals.
机构信息
School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea
出版信息
In Vivo. 2021 Nov-Dec;35(6):3039-3044. doi: 10.21873/invivo.12599.
Abstract
Certain diseases and age groups are associated with a higher incidence of cancer. Cancer prevention can be achieved using repositioned drugs that have anticancer ability, thereby reducing the incidence of cancer in susceptible individuals. This implies that the selection of repositioned drugs can have dual benefits: controlling pre-existing diseases and facilitating cancer prevention. This report outlines the rationale underlying drug repositioning for medications with an anticancer effect and discusses its advantages. We discuss repositioned drugs with anticancer effects that may contribute to cancer prevention in susceptible individuals and the general population with temporary, treatable conditions. The discussion of drug repositioning in this review should facilitate the initiation of clinical trials and lead to therapeutic application of such drugs to reduce the incidence of cancer in susceptible individuals.
摘要
某些疾病和年龄组与更高的癌症发病率相关。可以使用具有抗癌能力的重新定位药物来预防癌症，从而降低易感个体的癌症发病率。这意味着选择重新定位的药物可以带来双重好处：控制现有疾病和促进癌症预防。本报告概述了具有抗癌作用的药物重新定位的基本原理，并讨论了其优势。我们讨论了具有抗癌作用的重新定位药物，这些药物可能有助于预防易感个体和患有暂时性、可治疗疾病的一般人群的癌症。本综述中对药物重新定位的讨论应有助于启动临床试验，并导致此类药物的治疗应用，以降低易感个体的癌症发病率。
相似文献
1
Drug Repositioning With an Anticancer Effect: Contributions to Reduced Cancer Incidence in Susceptible Individuals.具有抗癌作用的药物再定位：减少易感个体癌症发病率的贡献。
In Vivo. 2021 Nov-Dec;35(6):3039-3044. doi: 10.21873/invivo.12599.
2
Drug repositioning in cancer: The current situation in Japan.药物重定位在癌症中的应用：日本的现状。
Cancer Sci. 2020 Apr;111(4):1039-1046. doi: 10.1111/cas.14318. Epub 2020 Feb 11.
3
[Development of a Novel Treatment for Neurological Disorders by Drug Repositioning].[通过药物重新定位开发神经疾病的新型治疗方法]
Brain Nerve. 2019 Sep;71(9):936-942. doi: 10.11477/mf.1416201385.
4
Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.卵巢癌药物重定位的现状和展望。
J Gynecol Oncol. 2019 Jan;30(1):e10. doi: 10.3802/jgo.2019.30.e10. Epub 2018 Oct 10.
5
Old wine in new bottles: Drug repurposing in oncology.旧酒换新瓶：肿瘤学中的药物再利用。
Eur J Pharmacol. 2020 Jan 5;866:172784. doi: 10.1016/j.ejphar.2019.172784. Epub 2019 Nov 12.
6
New drugs are not enough‑drug repositioning in oncology: An update.新药研发还不够——肿瘤药物再定位：最新进展。
Int J Oncol. 2020 Mar;56(3):651-684. doi: 10.3892/ijo.2020.4966. Epub 2020 Jan 20.
7
Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth.氟喹诺酮类药物从抗生素到抗癌药物的重新定位：一个被低估的事实。
Biomed Pharmacother. 2019 Mar;111:934-946. doi: 10.1016/j.biopha.2018.12.119. Epub 2019 Jan 8.
8
Recent advances in drug repositioning for the discovery of new anticancer drugs.用于发现新型抗癌药物的药物重新定位的最新进展。
Int J Biol Sci. 2014 Jun 10;10(7):654-63. doi: 10.7150/ijbs.9224. eCollection 2014.
9
Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities.尼氯硝唑再定位治疗癌症：挑战与基于纳米的药物传递机遇。
Eur J Pharm Biopharm. 2019 Aug;141:58-69. doi: 10.1016/j.ejpb.2019.05.004. Epub 2019 May 9.
10
Revisiting Non-Cancer Drugs for Cancer Therapy.重新审视用于癌症治疗的非癌症药物。
Curr Top Med Chem. 2016;16(19):2144-55. doi: 10.2174/1568026616666160216154441.
引用本文的文献
1
Low-Dose Perifosine, a Phase II Phospholipid Akt Inhibitor, Selectively Sensitizes Drug-Resistant ABCB1-Overexpressing Cancer Cells.低剂量Perifosine，一种II期磷脂酰肌醇-3-激酶（Akt）抑制剂，可选择性地使耐药的ABCB1过表达癌细胞敏感化。
Biomol Ther (Seoul). 2025 Jan 1;33(1):170-181. doi: 10.4062/biomolther.2024.069. Epub 2024 Dec 5.
2
First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations.一线联合应用低剂量双相药物治疗 ABCB1 过表达耐药性肿瘤人群。
Int J Mol Sci. 2023 May 7;24(9):8389. doi: 10.3390/ijms24098389.
3
The Combination Sorafenib-raloxifene-loratadine as a Novel Potential Therapeutic Approach Against Human Liver Cancer.索拉非尼-雷洛昔芬-氯雷他定联合用药作为一种新型潜在的肝癌治疗方法。
In Vivo. 2023 May-Jun;37(3):1156-1163. doi: 10.21873/invivo.13190.
4
Terconazole, an Azole Antifungal Drug, Increases Cytotoxicity in Antimitotic Drug-Treated Resistant Cancer Cells with Substrate-Specific P-gp Inhibitory Activity.特康唑，一种唑类抗真菌药物，可增加经抗有丝分裂药物处理的耐药癌细胞的细胞毒性，并具有底物特异性P-糖蛋白抑制活性。
Int J Mol Sci. 2022 Nov 9;23(22):13809. doi: 10.3390/ijms232213809.
5
Low-Dose Rifabutin Increases Cytotoxicity in Antimitotic-Drug-Treated Resistant Cancer Cells by Exhibiting Strong P-gp-Inhibitory Activity.低剂量利福布丁通过表现出较强的 P-糖蛋白抑制活性增加抗有丝分裂药物治疗耐药癌细胞的细胞毒性。
Int J Mol Sci. 2022 Jul 2;23(13):7383. doi: 10.3390/ijms23137383.
6
Contribution of Cancer-Targeting Drugs toward Faster Clinical Application.癌症靶向药物对加速临床应用的贡献。
Int J Mol Sci. 2022 Jun 9;23(12):6445. doi: 10.3390/ijms23126445.
本文引用的文献
1
Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer.社论：经美国食品药品监督管理局批准的用于P-糖蛋白过表达耐药癌症的药物重新定位
Front Oncol. 2021 Mar 17;11:632657. doi: 10.3389/fonc.2021.632657. eCollection 2021.
2
A Low Dose of Aripiprazole Has the Strongest Sensitization Effect Among 19 Repositioned Bipolar Drugs in P-gp-overexpressing Drug-resistant Cancer Cells.在P-糖蛋白过表达的耐药癌细胞中，低剂量阿立哌唑在19种重新定位的双相情感障碍药物中具有最强的致敏作用。
Anticancer Res. 2021 Feb;41(2):687-697. doi: 10.21873/anticanres.14820.
3
Low-Dose Crizotinib, a Tyrosine Kinase Inhibitor, Highly and Specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis and .低剂量克唑替尼，一种酪氨酸激酶抑制剂，通过诱导晚期凋亡高度且特异性地使过表达P-糖蛋白的化疗耐药癌细胞致敏。
Front Oncol. 2020 May 12;10:696. doi: 10.3389/fonc.2020.00696. eCollection 2020.
4
Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment.糖尿病与癌症：癌症应纳入常规糖尿病评估筛查。
Diabetes Metab J. 2019 Dec;43(6):733-743. doi: 10.4093/dmj.2019.0177.
5
Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study.阿巴西普治疗类风湿关节炎与癌症风险：一项世界范围的上市后观察性研究。
Rheumatology (Oxford). 2020 Sep 1;59(9):2360-2367. doi: 10.1093/rheumatology/kez604.
6
Histamine Receptor Antagonists, Loratadine and Azelastine, Sensitize P-gp-overexpressing Antimitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms.组胺受体拮抗剂氯雷他定和氮卓斯汀通过不同分子机制使过表达P-糖蛋白的抗有丝分裂药物耐药KBV20C细胞致敏。
Anticancer Res. 2019 Jul;39(7):3767-3775. doi: 10.21873/anticanres.13525.
7
Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.与HIV蛋白酶抑制剂奈非那韦联合治疗可显著增加耐药KBV20C癌细胞的晚期凋亡，且与P-糖蛋白抑制无关。
Anticancer Res. 2019 Jul;39(7):3757-3765. doi: 10.21873/anticanres.13524.
8
Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer.阿司匹林不仅是一种化学预防试剂，还是癌症特征的主要调控因子。
J Cancer Res Clin Oncol. 2019 Jun;145(6):1387-1403. doi: 10.1007/s00432-019-02902-6. Epub 2019 Apr 29.
9
Allergies and the Subsequent Risk of Cancer among Elderly Adults in the United States.美国老年人的过敏与随后的癌症风险。
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):741-750. doi: 10.1158/1055-9965.EPI-18-0887. Epub 2019 Jan 30.
10
Statin drugs to reduce breast cancer recurrence and mortality.他汀类药物降低乳腺癌复发和死亡率。
Breast Cancer Res. 2018 Nov 20;20(1):144. doi: 10.1186/s13058-018-1066-z.
Zotero 插件